Palliative care in COPD: an unmet area for quality improvement

Julia H Vermylen\(^1\)
Eytan Szmuilowicz\(^2\)
Ravi Kalhan\(^3\)

\(^1\)Department of Medicine, \(^2\)Section of Palliative Medicine, Department of Medicine, \(^3\)Asthma and COPD Program, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Abstract: COPD is a leading cause of morbidity and mortality worldwide. Patients suffer from refractory breathlessness, unrecognized anxiety and depression, and decreased quality of life. Palliative care improves symptom management, patient reported health-related quality of life, cost savings, and mortality though the majority of patients with COPD die without access to palliative care. There are many barriers to providing palliative care to patients with COPD including the difficulty in prognosticating a patient’s course causing referrals to occur late in a patient’s disease. Additionally, physicians avoid conversations about advance care planning due to unique communication barriers present with patients with COPD. Lastly, many health systems are not set up to provide trained palliative care physicians to patients with chronic disease including COPD. This review analyzes the above challenges, the available data regarding palliative care applied to the COPD population, and proposes an alternative approach to address the unmet needs of patients with COPD with proactive primary palliative care.

Keywords: advance care planning, primary palliative care, end-of-life care, advanced lung disease, quality of life, prognosis

Background

COPD is a complex, chronic disease defined by lung function limitation on spirometric testing that despite several recent breakthroughs in treatments remains an incurable and life-altering disease.\(^1,2\) Worldwide, 210 million people suffer from COPD,\(^3\) and in 2002, death from COPD was estimated to be the fifth leading cause of death comprising approximately 7.5% of overall deaths.\(^4\) Unlike ischemic heart disease and cerebrovascular disease that are decreasing in prevalence, death from COPD is increasing.\(^4,5\)

In the United States, for instance, age-standard death rates from COPD increased from 21.4 to 43.4 per 100,000, a change of over 100%, from 1970 to 2002. Conversely, age-standard death rates from stroke and heart disease decreased by 63.1% and 52.1% respectively over this same time frame.\(^6\)

Despite this large burden of disease, patients with COPD frequently have unmet needs at the end of life.\(^6–9\) Although palliative care has been shown to improve symptom burden, quality of life, and patient satisfaction for patients across many diseases,\(^10–15\) the majority of patients with COPD die without access to palliative care.\(^7\) This review focuses on evaluating the current burden of disease, reviews what is known about palliative care and COPD, and argues that incorporation of palliative care into COPD management could improve overall quality of care delivered to people living with COPD.

Palliative care: what is it and what can it do?

Palliative care began in the 1960s with the beginning of the hospice movement and was focused on symptom management at the end of life.\(^16\) Today, however, the World Health Organization (WHO) defines palliative care as:
An approach that improves the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual.\textsuperscript{17}

Using this new framework, palliative care now extends throughout the course of a patient’s illness from disease onset through the terminal phase of illness.

Proactive approaches to palliative care involve a variety of care models. While some models include direct interactions with a trained palliative care physician, other models employ a multidisciplinary team of social workers, physicians, and nurses to provide intensive outpatient resources. All care models focus on improving the symptoms and psychosocial needs of the patient and also actively engage the family and caregivers in training and support as shown in Figure 1.

Outpatient palliative care improves patient quality of life, decreases symptom burden, and in some cases even improves mortality.\textsuperscript{12,15,18,19} There are also potential significant financial benefits to the proactive use of palliative care. Kaiser Permanente, a US-based vertically organized health maintenance organization, found that the care for patients living with serious illness who received a multidisciplinary palliative intervention cost US$6,580 less per patient in the last months of life, the equivalent of a 45% cost reduction in the intervention cohort compared to the baseline cohort.\textsuperscript{20} Among patients with metastatic non-small-cell lung cancer (NSCLC), proactive palliative care has been shown to not only decrease costs but also improve mortality.\textsuperscript{12} The findings within NSCLC are so profound that it is now considered standard of care to include early introduction of palliative care along-side more aggressive treatment.\textsuperscript{21} The American Thoracic Society\textsuperscript{22} and the recent Global Initiative for Obstructive Lung Disease statement\textsuperscript{2} have called for increased palliative care services for patients living with COPD but at this time proactive palliative care for patients with COPD is rare and far from standard of care.

The burden of COPD

Not only is COPD a leading case of mortality, it is also a leading cause of disability throughout the world. In 2002 it was ranked as the eleventh leading cause of disability life adjusted years and is projected to increase to the seventh worldwide leading cause by 2030.\textsuperscript{4} In 2014, a systematic review of the indirect costs of COPD found that 13%–18% of individuals with COPD in the United States reported limitations in their ability to work.\textsuperscript{21}

Across many studies of patients with COPD at the end of life, severe breathlessness is profoundly distressing to patients and is often poorly controlled and under-addressed by care providers.\textsuperscript{6,12,23,24} In a cross-sectional study evaluating symptom burden in Sweden, approximately 90% of patients...
with stable lung function report shortness of breath.\textsuperscript{23} Shortness of breath is not only a distressing symptom to patients but is also associated with decreased health-related quality of life (HRQoL) and a risk factor for further COPD exacerbations and functional decline.\textsuperscript{12,25}

Patients with COPD have a large burden of symptoms beyond breathlessness including fatigue, cough, and pain. Even among patients with minimal decrements in lung function, many report symptoms of cough, dry mouth, and fatigue.\textsuperscript{8} In the Swedish cross-sectional study, patients with moderate to severe airflow limitations were found to have on average 7.9 symptoms at any given time and patients with severe and very severe airflow limitations typically reported between nine and 14 symptoms.\textsuperscript{23} In an international survey of 12 countries, 50\% of countries reported that the average patient had severe to very severe burden of symptoms when scored with the COPD Assessment Test.\textsuperscript{24} This burden of symptoms is similar to or worse than that reported in many diseases including NSCLC and heart failure though referral to palliative care subspecialty services is significantly reduced compared to these two conditions.\textsuperscript{7,8,26,27}

Unrecognized and uncontrolled anxiety and depression are major symptoms that impact quality of life in COPD. The prevalence of anxiety and depression among the COPD population varies greatly between studies though is consistently found to be increased compared to other chronic illnesses.\textsuperscript{26,28} Depression is estimated to be as high as 40\% among all stages of COPD and as high as 62\% among patients who are prescribed domiciliary oxygen.\textsuperscript{28,29} Anxiety is similarly found to be as high as 19\% across patients with stable COPD though as high as 75\% among patients with severe airflow limitation.\textsuperscript{26} Anxiety and depression are both associated with poor health outcomes including increased frequency of hospital admission, decreased quality of life, and early death.\textsuperscript{28}

The burden of significant symptoms and comorbid health conditions in COPD are comparable or worse than other chronic illnesses including heart failure, HIV, and metastatic cancer. Patients with COPD, however, are less likely to have adequate treatment of symptoms at the end of their life, are more likely to have a decreased HRQoL, and are significantly less likely to receive specialist palliative care referral.\textsuperscript{7} Patients with COPD are more likely to have aggressive care at the end of life including mechanical ventilation and stays in the intensive care unit compared to those with lung cancer.\textsuperscript{30} COPD patients are also more likely to receive cardiopulmonary resuscitation (CPR) at the end of life though evidence from the Study to Understand Prognosis and Preferences for Outcomes and Treatments (SUPPORT) showed no difference in preferences for mechanical ventilation or wishes to receive CPR between COPD patients and those with lung cancer.\textsuperscript{30} Patients with COPD, therefore, are frequently under-supported with significant symptom burden, disability, quality of life impairment, and aggressive use of health care resources at the end of their life.

The current state of COPD and palliative care

Despite refractory symptoms and recurrent hospitalizations, patients with COPD die without access to palliative care.\textsuperscript{7} Many physicians view palliative care only as care given to actively dying individuals rather than a multidisciplinary approach that focuses on a patient’s quality of life and burden of symptoms as well as a means to provide psychosocial support for patients and their caregivers. Physicians have difficulty predicting which patients are at highest risk of dying and have difficulty discussing these concerns with their patients. Additionally, the current health systems are not designed to adequately reimburse palliative care treatments for patients with COPD. Consequently, patients with COPD are often not referred to palliative care resources and have unmet needs at the end of life.\textsuperscript{6,9}

This review focuses on the many barriers to providing palliative care including the difficulties of prognostication and communication as well as the obstacles within the current health systems. Although specific pharmacotherapy options for managing symptoms of COPD are outside the scope of this article, this review lays out a new framework for delivery of palliative care. Additionally, this review specifically discusses how to identify patients appropriate for palliative care as well as how to screen for and address the unmet needs of patients with COPD.

Barriers to providing palliative care to patients with COPD

Difficulties of prognosis

The variable and prolonged course of COPD patients makes prognostication difficult for both physicians, patients, and their caregivers, and makes addressing end-of-life goals difficult. Unlike the typical patient with metastatic cancer who classically has a predictable, steady decline after diagnosis, the natural history of COPD is typically protracted and heterogeneous.\textsuperscript{31} Often, patients are first diagnosed with COPD after developing breathlessness in the outpatient setting. The diagnosis is made with lung function testing though the...
degree of lung function impairment is often not correlated to
the patient’s symptom burden or disease course. Patients
experience a continuous slow decline in lung function accom-
panied by a slow accumulation of symptoms punctuated by
episodes of acute exacerbation and decline with only partial
recovery.

While patients often experience a slow decline in func-
tional status they also suffer episodes of acute exacerbation
that may require hospitalization. Although patients are at
high risk of death during and just following these exacerba-
tions, patients will often survive many acute episodes before
their time of death. The episodic course of COPD makes
the exact time of death often feel unexpected and abrupt for
both families and physicians since the patient had survived
seemingly similar episodes in the past. The SUPPORT study
reinforced this finding as it showed that 5 days before death,
physicians estimated that their patients with COPD were more
than 50% likely to be alive in 6 months. Patients with lung
cancer, in the same study however, were predicted to be less
than 10% likely to be alive in 6 months.

The difficulty in prognostication causes both patients
and physicians to struggle to recognize the terminal phase
of illness. For this reason, approaches that limit palliative
care resources to the final stages of life overlook many dying
patients as their terminal phase of illness goes unrecognized.
For this reason, an approach whereby COPD health care pro-
viders adopt proactive palliative care that does not rely on the
precise prognostication and identification of imminent death
in COPD would likely result in greater access to palliative
care services for people living with COPD.

Difficulties with communication
Communication is often compromised between patients
with COPD and their physicians. Due to the difficulty of
prognostication, physicians are often hesitant to discuss their
patient’s disease course and expected course of illness. Physicians also report concern about removing hope for their
patient and fear that this will have detrimental effects on their
physician’s quality of life (QoL) and mortality. Even among
physicians who feel their patients would benefit from goals
of care conversations, many report inadequate training and
insufficient time to approach these conversations.

Patients are also reluctant to discuss the end of their life. Commonly cited barriers include not knowing which physi-
cian they should speak to about their wishes, not knowing
the extent of their own wishes, as well as wanting to focus
on curative treatments instead of thinking about COPD as
a life-limiting illness. In a qualitative study of patients with
COPD, many were quoted saying “I would rather concentrate
on staying alive than talk about death”. In review of the
Phase II intervention of the SUPPORT trial, only 23% of
patients had discussed their wishes regarding CPR before
hospitalization. Among patients who had not discussed their
preferences, only 42% were interested in doing so leaving
a majority of patients, approximately 58%, uninterested in
having a conversation regarding CPR preferences. Interest-
ingly, however, 87% of patients who had not and did not
want to discuss their preferences wanted to avoid prolonged
mechanical ventilation and 25% wanted to avoid resuscitation
completely. Additionally, 80% of patients who did not want
to discuss their end-of-life wishes also had not completed
advanced directives. Although patients may not initially
be interested in discussing advanced directives with their
physicians, this study suggests that many patients still have
unexpressed wishes that may not be respected if the conver-
sation is not broached delicately.

Despite the many barriers to communication from both
the physician and patient perspective, patients express the
desire to have emotional support and discuss end-of-life care
with their physicians. In particular COPD patients report
particular deficits in discussing prognosis as well as the dying
process with their physicians.

Health-systems issues
There is great variability in access to palliative care world-
wide. The UK for instance, the founder of the Hospice
movement, is rather progressive with one of the highest
services to population ratios of 15 services (defined as hos-
pital units, palliative care teams, home care teams etc) per
million inhabitants. In other parts of the world, however,
such as Sub-Saharan Africa, palliative care is thought to be
a luxury and not a basic right of an individual and there are
no national palliative care services available. Even in areas
of the world that have well-defined palliative care resources,
many are limited to individuals in the terminal phase of illness
or limited to particular diagnoses such as cancer, making
a proactive palliative care approach in a chronic medical
condition like COPD challenging. In the USA, current
reimbursement structures are set up to fund curative treat-
ment or terminal illness. There are not, however, consistent
systems in place to reimburse providers for palliative treat-
ment throughout the course of a patient’s illness or to sup-
port the holistic and psychosocial aspects of a patient’s care.
Consequently, even if patients and physicians are discussing
symptom management, improved home recourses, support
for primary caregiver, and long-term care planning, they are
often unable to be reimbursed for these extensive recourses and thus are unable to address these unmet needs.48

Palliative care and COPD
Identifying patients appropriate for referral to palliative care: the surprise question
Prognostication of the exact time of death will always be difficult for the clinician and the patient with COPD. When palliative care is included not only during the terminal phase of illness but also during the last few stages of disease, the difficulties of prognostication are often alleviated. One proposed method for identifying patients appropriate for proactive palliative care is the use of “the surprise question”. This method, encourages physicians to ask “would I be surprised if my patient were to die in the next 12 months?”49 If the answer is no, proactive palliative care should be considered.49,50 The “surprise question” has been adopted by the UK national policies to be used as a supplementary screening tool for primary care physicians to identify patients who would benefit from early palliative care.51 It has also been studied in other diseases including end-stage renal disease and has been shown to aid in the prediction of short-term mortality risk in hemodialysis patients.52

Twelve-month predictors of mortality
Many studies have looked into predictors of 12-month mortality as well as predictors of mortality post-hospitalization for an acute exacerbation of COPD. Consistently authors report that patients with advanced age, cardiac comorbidity, low forced expiratory volume in 1 second, low body mass index, poor functional status, and poor HRQoL were at increased risk of dying within the following year.35,53–56 Although each individual’s mortality will vary, Table 1 identifies flags to recognize patients that would benefit from proactive supportive palliative care interventions.

Refractory symptoms
In addition to those patients with high risk of death within the next year of life, patients with symptoms that are refractory to initial therapy would benefit from an early palliative care approach. As discussed earlier, patients with COPD have a multitude of symptoms ranging from dyspnea fatigue, cachexia, anxiety, and depression. Although some patients may respond quickly to pharmacotherapy, opioids, and oxygen therapy, others continue to suffer after initial steps are taken. In these patients, intensive outpatient support that can be provided by a palliative care team should be considered.

New models of care
Though the focus of both inpatient and outpatient palliative care has been on oncology patients, there have been a few studies evaluating palliative care and holistic interventions within the COPD population.

A recent study published in December 2014 was a single-blind randomized controlled trial for patients with advanced disease and refractory breathlessness. In this study both patients with cancer and advanced chronic illness, including COPD, were enrolled and followed for a 6-week intervention. The support services involved a multidisciplinary team including pulmonologists, palliative care specialists, nurses, physical therapists, respiratory therapists, and occupational therapists. Patients were screened at routine clinic appointments and given a breathlessness pack including medications, a crisis plan, as well as a poem. Patients then received a home assessment 2–3 weeks after enrollment by a physical therapist and occupational therapist and a follow-up appointment with the pulmonologist and palliative care physician at 4 weeks after enrollment. Not surprisingly, patients in the breathlessness support arm of the trial had a significant reduction in their burden of symptoms. Surprisingly, unlike the cancer patients involved in the intervention who had no change in mortality, patients with COPD had a significant mortality benefit upon 6-month follow-up; 100% of COPD patients in the breathlessness support arm were alive at 6 months whereas only 79% were found to be alive in the control cohort.57 Similar mortality benefits were found for all non-oncologic patients

Table 1 Triggers to begin or intensify proactive palliative resources for patients with COPD

<table>
<thead>
<tr>
<th>Trigger</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;75</td>
<td>35,54,54,61</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>35,54,55,61–66</td>
</tr>
<tr>
<td>Change 6-minute walk by 50 m</td>
<td>55</td>
</tr>
<tr>
<td>Functional dependence and patient reported minimal physical activity</td>
<td>35,55,60,67</td>
</tr>
<tr>
<td>Poor health-related quality of life</td>
<td>35,57,65,68</td>
</tr>
<tr>
<td>FEV&lt;sub&gt;1&lt;/sub&gt; &lt; 30%</td>
<td>54,66</td>
</tr>
<tr>
<td>BMI &lt;20%</td>
<td>65,69</td>
</tr>
<tr>
<td>≥ 1 hospitalization within last year</td>
<td>25,65</td>
</tr>
</tbody>
</table>

Notes: Comorbidities include diabetes, cardiovascular disease (ischemic heart disease, congestive heart failure), end-stage chronic renal disease. Patient reported minimal physical activity defined as spending more time in a recliner chair or bed than not during the day. Methods to assess health-related quality of life include the St George’s Respiratory Questionnaire, Chronic Respiratory Disease Questionnaire, and the Breathing Problems Questionnaire.

Abbreviations: FEV<sub>1</sub>, forced expiratory volume in 1 second; BMI, body mass index.
Another effective tool has been the use of pulmonary rehabilitation (PR). PR has been studied in the stable COPD population as well as in the post-hospitalization of acute exacerbation management where it has been found to be effective at reducing symptoms and re-hospitalization as well as improving HRQoL. In many studies PR has also been found to reduce symptoms of anxiety and depression by increasing the patient’s functional status and allowing them to engage in their community. Although PR is not typically classified as a palliative care measure, it is already addressing many of the unmet needs of COPD patients. It is a model of care that already involves a multidisciplinary approach after a vulnerable time in a patient’s illness. PR programs, however, do not typically assess patients for concurrent depression and anxiety and do not routinely engage patients in end-of-life discussions at this time. With further resources such as scheduled palliative care visits during PR, this could be an ideal time and place to introduce palliative care to COPD patients.

**Conclusion: where to go from here**

In order to improve the suffering of end-stage COPD patients, palliative care needs to be incorporated earlier into the trajectory of illness. Currently patients and physicians are waiting until identification of the terminal phase of illness that is often indistinguishable from the slow chronic decline with repeated acute exacerbations characteristic of this disabling disease. Opportunities are missed to decrease disease associated disability and suffering for patients. Instead, patients are left with uncontrolled symptoms, disability, anxiety and depression, and repeated hospitalizations at the end of their life. Proactive palliative care must be incorporated to address the needs of patients during the last few years of life in order to prevent suffering and excess spending at the end of life.

Proactive palliative care should be incorporated early into the patient’s illness as shown in Figure 2 to address complex refractory symptoms, advance care planning, and increase outpatient resources for patients and caregivers. Not all patients who would benefit from proactive palliative support need to be referred to palliative care physicians. Unfortunately given the health systems barriers discussed previously, this will not be feasible in the current system of care in many nations. Instead, primary care providers as well as specialty pulmonologists should be trained and capable of screening patients who would benefit from proactive outpatient supportive care and provide primary palliative care as outlined in Table 2. These frontline providers should provide increased focus on symptom management, advance care planning, and support for patients as part of comprehensive COPD care. Interdisciplinary teams including nursing, social work, respiratory, and physical therapists as well as chaplains or pastoral care should be engaged to meet the complex needs of their patients.
Further research is needed to assess the improvement in patients’ symptoms, QoL and mortality as well as the proposed financial benefits of proactive palliative care in the treatment of COPD. Although we know patients with COPD are suffering and proactive palliative care has been used in other diseases, few research has been performed to prove the benefits of proactive palliative care in COPD. The PROLONG study is an ongoing prospective cluster controlled trial involving six hospitals in the Netherlands using proactive palliative care. This will be the first study of its kind to use a proposed set of clinical indicators to prompt proactive palliative care and will assess the effects on mortality and QoL of study participants. This is an exciting area of research that will provide new insight into the power of proactive palliative care in COPD.

Disclosure

JH Vermylen and E Szmulowicz have no disclosures to report in this work. R Kalhan reports personal fees from Forrest Laboratories, grants and personal fees from Boehringer Ingelheim, grants from GlaxoSmithKline and from PneumRx, personal fees from Merck and from Quantia Communications, and grants from Spiration, outside the submitted work.

References


